Alogliptin
Alogliptin, sold under the brand names Nesina and Vipidia,) is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.

In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about increased risk of heart failure. It was developed by Syrrx, a company which was acquired by Takeda Pharmaceutical Company in 2005.
Q575062
anti-diabetic drug
Concept
Q419770
DPP-4 inhibitor
Concept
Q204711
Food and Drug Administration
Concept
Q181754
heart failure
Concept
Q899133
Takeda Pharmaceutical Company
ORG
Q4734170
Alogliptin
Concept
Q4734170
Alogliptin
Concept
Q4734170
Alogliptin
Concept
2016-04-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
April 2016
DATE
2005-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2005
DATE
-4^^http://www.w3.org/2001/XMLSchema#decimal
-4
NUMBER
subject has role
subject has role
subclass of